Clinical trial
Zoledronate With Atorvastatin in Renal Cell Carcinoma
NCT00490698 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00490698 |
|---|---|
| Title | Zoledronate With Atorvastatin in Renal Cell Carcinoma |
| Official title | Bone-Targeted Therapy Combining Zoledronate With Atorvastatin in Renal Cell Carcinoma: A Phase II Study |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer, Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Zoledronate, Atorvastatin |
| Enrollment | 11 |
| Start date | Oct 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Jun 25, 2007 |
| Last update posted | Mar 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: